Sign in Subscribe
Coronaviruses

Investigation Expands into Emergent BioSolutions Manufacturing Problems

Strategic Insights

— 1 min read

The U.S. House of Representatives Committee on Oversight and Government Reform has launched an expanded investigation into manufacturing problems at Emergent BioSolutions' Bayview facility. Rep. Carolyn B. Maloney and Rep. James E. Clyburn sent letters to the top executives of AstraZeneca and Johnson and Johnson, citing deficient controls at the facility that could lead to contamination. The investigation follows a scathing inspection report issued by the FDA on April 20, 2021, which resulted in the hold on manufacturing at the facility for the last two months.

Key Takeaways:

  • The investigation is focused on Emergent BioSolutions' manufacturing problems at the Bayview facility, which produced vaccines for AstraZeneca and Johnson and Johnson, worth up to $1.5 billion.
  • More than 85 million vaccine doses have been destroyed, and an additional 60 million doses are being held back to determine if they are safe.
  • Chairwoman Maloney and Chairman Clyburn are concerned about the impact of Emergent's mistakes on global vaccination efforts and public perceptions regarding the safety and efficacy of the vaccines.
  • The Chairs are also investigating the circumstances that led AstraZeneca and Johnson and Johnson to sign contracts with Emergent to produce their respective vaccines.
  • Initial findings from the investigation, released on May 19, 2021, indicate that the failure to address serious deficiencies at Emergent's Bayview facility led to the destruction of millions of doses due to contamination.
  • Top Emergent executives acknowledged prior awareness of risks but sought to downplay the contamination that occurred during a Select Subcommittee hearing.

Statistics:

  • More than 85 million vaccine doses have been destroyed.
  • An additional 60 million doses are being held back to determine if they are safe.
  • Up to $1.5 billion worth of vaccine production contracts between Emergent, AstraZeneca, and Johnson and Johnson.
  • The facility has been on hold for manufacturing for the last two months following the FDA's inspection report on April 20, 2021.

Sources:

  • A letter to AstraZeneca (no date provided in the source material).
  • A letter to Johnson and Johnson (no date provided in the source material).
  • The U.S. House of Representatives Committee on Oversight and Government Reform.

Read more